tbuckley/cabot-search huggingface dataset:
Application of the Immunoscore as prognostic tool for hepatocellular carcinoma
Authors: Annacarmen Petrizzo, Luigi Buonaguro
Journal: Journal for ImmunoTherapy of Cancer (2016)

To date, the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) tumor, nodes, metastasis (TNM) classification represents the standard system for evaluation of prognosis in solid tumors. However, the clinical outcome can be significantly different in patients with the same TNM stage. Therefore, many efforts have been made aiming to define new prognostic parameters. Indeed, analyses conducted in large cohorts of colorectal cancer patients emphasized the prognostic value of tumor-infiltrating lymphocytes, leading to the development of a prognostic score referred to as "Immunoscore". In this commentary, we recapitulate the study by Gabrielson and colleagues, recently published in Cancer Immunology Research, addressing the role of intratumoral CD3+ and CD8+ T cells as well as as prognostic markers for hepatocellular carcinoma. The authors demonstrate that Immunoscore represents a valuable prognostic marker in patients with hepatocellular carcinoma who have undergone primary tumor resection, supporting its application in a tumor setting other than colorectal cancer.
A Panel of Artificial Antigen Presenting Cells (AAPC) Permits Immediate Sensitization and Rapid Generation of Virus-Specific T-Cells of Desired HLA Restriction for Adoptive Immunotherapy.
Authors: Aisha N. Hasan, Wouter J. Kollen, Deepa Trivedi, A. Selvakumar, Michel Sadelain, Richard J. O’Reilly
Journal: Blood (2006)
Unusual Presentations of Lung Cancer
Authors: Pavan Reddy, Gregory P. Kalemkerian
Journal: Journal of Clinical Oncology (2002)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.23.4597 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12454118 Unusual Presentations of Lung Cancer Case 1. Diabetes Insipidus as the Initial Manifestation of Non-Small-Cell Lung Cancer Pavan ReddyxPavan ReddySearch for articles by this author , Gregory P. KalemkerianxGregory P. KalemkerianSearch for articles by this author Show More University of Michigan, Ann Arbor, MI https://doi.org/10.1200/JCO.2002.20.23.4597 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
Human Erythroblasts Generated in Vitro Remain Functional with a Normal Karyotype 8 Years after Cryopreservation: Implications for Ex Vivo Generated Erythroid Transfusion Products.
Authors: Massimo Sanchez, Amanda Leblanc, Annalisa Mancini, Francesca Masiello, Valentina Tirelli, Giovanni Migliaccio, Anna Rita Migliaccio, Vesna Najfeld, Carolyn Whitsett
Journal: Blood (2008)
Apoptin Induced Tumour Specific Killing Via Protein Kinase C Isoforms: A Potential Therapeutic Strategy In Plasma Cell Dyscrasias
Authors: Jie Jiang, Daryl Cole, Nigel Westwood, Lee Macpherson, Farzin Farzaneh, Ghulam J. Mufti, Mahvash Tavassoli, Joop Gaken
Journal: Blood (2010)
Number of Lymphoma-Associated-Macrophages (LAM) Is An Independent Predictor of Survival in Patients with Mantle Cell Lymphoma (MCL).
Authors: Pedro Farinha, Stephen Opat, Merrill Boyle, Nathalie Johnson, Hilary O'Leary, Lin Wang, James R. Cook, Raymond R. Tubbs, Joseph M. Connors, Randy D. Gascoyne
Journal: Blood (2009)
Characterizing the Pattern of Anomalies in Congenital Zika Syndrome for Pediatric Clinicians
Authors: Cynthia A. Moore, J. Erin Staples, William B. Dobyns, André Pessoa, Camila V. Ventura, Eduardo Borges da Fonseca, Erlane Marques Ribeiro, Liana O. Ventura, Norberto Nogueira Neto, J. Fernando Arena, Sonja A. Rasmussen
Journal: JAMA Pediatrics (2016)

Zika virus infection can be prenatally passed from a pregnant woman to her fetus. There is sufficient evidence to conclude that intrauterine Zika virus infection is a cause of microcephaly and serious brain anomalies, but the full spectrum of anomalies has not been delineated. To inform pediatric clinicians who may be called on to evaluate and treat affected infants and children, we review the most recent evidence to better characterize congenital Zika syndrome.
Uncommon Presentations of Malignancies
Authors: Thein H. Oo, Leo S. Aish, Douglas Schneider, Hani Hassoun
Journal: Journal of Clinical Oncology (2003)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2003.07.103 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12885821 Uncommon Presentations of Malignancies CASE 2. CARCINOID TUMOR PRESENTING WITH BONE MARROW METASTASES Thein H. OoxThein H. OoSearch for articles by this author , Leo S. AishxLeo S. AishSearch for articles by this author , Douglas SchneiderxDouglas SchneiderSearch for articles by this author , Hani HassounxHani HassounSearch for articles by this author Show More The Division of Hematology and Medical Oncology, Department of Medicine, St Elizabeth’s Medical Center of Boston, Boston, MA; and the Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY https://doi.org/10.1200/JCO.2003.07.103 First Page Full Text PDF Figures and Tables © 2003 by American Society of Clinical Oncology
The Tyrosine Kinase c-Met Is Selectively Expressed on Motile Hematopoietic Progenitors Following G-CSF Administration and Promotes Mobilization by Regulating Stem Cell Niche Components.
Authors: Melania Tesio, Alexander Kalinkovich, Amir Schajnovitz, Ayelet Dar, Orit Kollet, Polinna Goichberg, Isabelle Petit, Silvia Giordano, Massimo Aglietta, Wanda Piacibello, Tsvee Lapidot
Journal: Blood (2006)
Epidemiology and Clinical Characteristics of Patients with Multiple Myeloma. Results of a Prospective Multicenter Study in Russian Federation
Authors: Maxim V. Solovev, Larisa P. Mendeleeva, Olga S. Pokrovskaya, Eduard Gemdzhian, Elena Volodicheva, Lyudmila V. Anchukova, Svetlana N. Menshakova, Svetlana M. Osyunikhina, Vladimir V. Voytsekhovski, Valeri G. Savchenko
Journal: Blood (2015)
Urinary Protein Levels in Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Predict Severe Disease Related Complications at Myeloma Progression
Authors: Angelo Belotti, Michele Malagola, Claudia Crippa, Ilaria Prezioso, Francesca Schieppati, Rossella Ribolla, Vincenza Orlando, Domenico Russo, Giuseppe Rossi
Journal: Blood (2015)
Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients
Authors: Christina Bluemel, Stefanie Hahner, Britta Heinze, Martin Fassnacht, Matthias Kroiss, Thorsten A. Bley, Hans-Juergen Wester, Saskia Kropf, Constantin Lapa, Andreas Schirbel, Andreas K. Buck, Ken Herrmann
Journal: Clinical Nuclear Medicine (2016)

Purpose Adrenocortical carcinoma (ACC) is a rare but aggressive endocrine tumor with limited treatment options. Preclinical studies confirmed overexpression of the chemokine receptor 4 (CXCR4) in this cancer type. This study aimed to analyze the role of CXCR4 imaging using 68Ga-pentixafor for ACC staging and selection of patients for CXCR4-directed endoradiotherapy. Methods Thirty patients with histologically proven advanced, metastasized ACC underwent 18F-FDG PET/CT and 68Ga-pentixafor PET/CT within a time interval of 3 ± 4 days to evaluate suitability for CXCR4-directed endoradiotherapy. Scans were analyzed retrospectively for visual extent of ACC and SUVmax/mean of the tumor lesions. 68Ga-pentixafor PET was compared with 18F-FDG PET, the reference imaging standard. All patients were rated for suitability of CXCR4-directed endoradiotherapy considering patient’s history, previous treatment, and CXCR4 expression of FDG-positive lesions compared with background activity within the same organ. Results All patients had lesions that were positive for both 18F-FDG and 68Ga-pentixafor PET and were rated as positive for disease. In 2 patients (7%), 68Ga-pentixafor PET identified more lesions compared with 18F-FDG PET. In 5 patients (17%) and 10 patients (33%), complementary and comparable information, respectively, was provided by dual-tracer imaging. In 13 patients (43%), more tumor lesions were identified by 18F-FDG PET compared with 68Ga-pentixafor PET. The 18F-FDG uptake of the malignant lesions was significantly higher (P < 0.01) than the SUVmax/mean for 68Ga-pentixafor. Overall, 70% of the patients were rated as suitable or potentially suitable for CXCR4-directed treatment. Conclusions 68Ga-pentixafor allows in vivo imaging of CXCR4 expression in patients with advanced ACC and may serve as companion diagnostic tool in selecting patients for potential CXCR4-directed endoradiotherapy. Seventy percent of the patients with advanced, metastasized ACC may be suitable for a CXCR4-directed treatment after failure of standard treatment options.
Long-Term Dosing of AMG 531 Is Effective and Well Tolerated in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura.
Authors: James B. Bussel, David J. Kuter, James N. George, Louis M. Aledort, Alan E. Lichtin, Roger M. Lyons, Jorge Nieva, Jeffrey S. Wasser, Emanuelle Bourgeois, Mies Kappers-Klunne, Francois LeFrere, Martin R. Schipperus, Reggie Kelly, Jenny Christal, Chien-Feng Chen, Janet L. Nichol
Journal: Blood (2005)
Myc Represses miR15a/Mir-16-1 Expression through Recruitment of HDAC3 In Mantle Cell Lymphoma
Authors: Xinwei Zhang, Xia Chen, Jianhong Lin, Tint Lwin, Scott A Ely, Selina Chen-Kiang, William S. Dalton, Edward Seto, Kenneth Wright, Eduardo M. Sotomayor, Jianguo Tao
Journal: Blood (2010)
Culture on 3D Chitosan‐Hyaluronic Acid Scaffolds Enhances Stem Cell Marker Expression and Drug Resistance in Human Glioblastoma Cancer Stem Cells
Authors: Kui Wang, Forrest M. Kievit, Ariane E. Erickson, John R. Silber, Richard G. Ellenbogen, Miqin Zhang
Journal: Advanced Healthcare Materials (2016)

The lack of in vitro models that support the growth of glioblastoma (GBM) stem cells (GSCs) that underlie clinical aggressiveness hinders developing new, effective therapies for GBM. While orthotopic patient‐derived xenograft models of GBM best reflect in vivo tumor behavior, establishing xenografts is a time consuming, costly, and frequently unsuccessful endeavor. To address these limitations, a 3D porous scaffold composed of chitosan and hyaluronic acid (CHA) is synthesized. Growth and expression of the cancer stem cell (CSC) phenotype of the GSC GBM6 taken directly from fresh xenogratfs grown on scaffolds or as adherent monolayers is compared. While 2D adherent cultures grow as monolayers of flat epitheliod cells, GBM6 cells proliferate within pores of CHA scaffolds as clusters of self‐adherent ovoid cells. Growth on scaffolds is accompanied by greater expression of genes that mediate epithelial–mesenchymal transition and maintain a primitive, undifferentiated phenotype, hallmarks of CSCs. Scaffold‐grown cells also display higher expression of genes that promote resistance to hypoxia‐induced oxidative stress. In accord, scaffold‐grown cells show markedly greater resistance to clinically utilized alkylating agents compared to adherent cells. These findings suggest that our CHA scaffolds better mimic in vivo biological and clinical behavior and provide insights for developing novel individualized treatments.
Visual Outcomes after Vitrectomy for Terson Syndrome Secondary to Traumatic Brain Injury
Authors: Raja Narayanan, Stanford C. Taylor, Ashraya Nayaka, Riddhima Deshpande, Daniel St. Aubin, Frank N. Hrisomalos, Jonathan Hu, Rithwick Rajagopal, Asheesh Tewari, Rajendra S. Apte
Journal: Ophthalmology (2016)
Delayed Hemolytic Transfusion Reaction in Sickle Cell Disease Patients: Evidence of An Emerging Syndrome with Suicidal Erythrocyte Death
Authors: France Noizat-Pirenne, Philippe Chadebech, Anoosha Habibi, Dora Bachir, Ruben Nzouakou, Frederic Galacteros, Philippe Bierling
Journal: Blood (2008)
Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
Authors: Jeffrey R. Infante, Antoine Hollebecque, Sophie Postel-Vinay, Todd M. Bauer, Elizabeth M. Blackwood, Marie Evangelista, Sami Mahrus, Franklin V. Peale, Xuyang Lu, Srikumar Sahasranaman, Rui Zhu, Yuan Chen, Xiao Ding, Elaine R. Murray, Jennifer L. Schutzman, Jennifer O. Lauchle, Jean-Charles Soria, Patricia M. LoRusso
Journal: Clinical Cancer Research (2016)

Purpose: Chk1 inhibition potentiates DNA-damaging chemotherapy by overriding cell-cycle arrest and genome repair. This phase I study evaluated the Chk1 inhibitor GDC-0425 given in combination with gemcitabine to patients with advanced solid tumors.Experimental Design: Patients received GDC-0425 alone for a 1-week lead-in followed by 21-day cycles of gemcitabine plus GDC-0425. Gemcitabine was initially administered at 750 mg/m2 (Arm A), then increased to 1,000 mg/m2 (Arm B), on days 1 and 8 in a 3 + 3 + 3 dose escalation to establish maximum tolerated dose (MTD). GDC-0425 was initially administered daily for three consecutive days; however, dosing was abbreviated to a single day on the basis of pharmacokinetics and tolerability. TP53 mutations were evaluated in archival tumor tissue. On-treatment tumor biopsies underwent pharmacodynamic biomarker analyses.Results: Forty patients were treated with GDC-0425. The MTD of GDC-0425 was 60 mg when administered approximately 24 hours after gemcitabine 1,000 mg/m2 Dose-limiting toxicities included thrombocytopenia (n = 5), neutropenia (n = 4), dyspnea, nausea, pyrexia, syncope, and increased alanine aminotransferase (n = 1 each). Common related adverse events were nausea (48%); anemia, neutropenia, vomiting (45% each); fatigue (43%); pyrexia (40%); and thrombocytopenia (35%). The GDC-0425 half-life was approximately 15 hours. There were two confirmed partial responses in patients with triple-negative breast cancer (TP53-mutated) and melanoma (n = 1 each) and one unconfirmed partial response in a patient with cancer of unknown primary origin.Conclusions: Chk1 inhibition with GDC-0425 in combination with gemcitabine was tolerated with manageable bone marrow suppression. The observed preliminary clinical activity warrants further investigation of this chemopotentiation strategy. Clin Cancer Res; 23(10); 2423-32. ©2016 AACR.
Persistent effects of playing football and associated (subconcussive) head trauma on brain structure and function: a systematic review of the literature
Authors: A A Tarnutzer, D Straumann, P Brugger, N Feddermann-Demont
Journal: British Journal of Sports Medicine (2016)

Aim/objective There is ongoing controversy about persistent neurological deficits in active and former football (soccer) players. We reviewed the literature for associations between football activities (including heading/head injuries) and decline in brain structure/function. Design Systematic literature review. Data sources MEDLINE, Embase, PsycINFO, CINAHL, Cochrane-CRCT, SportDiscus, Cochrane-DSR=4 (accessed 2 August 2016). Eligibility criteria for selecting studies Original studies reporting on football-related persistent effects on brain structure/function. Results from neurocognitive testing, neuroimaging and EEG were compared with controls and/or correlated with heading frequency and/or head injuries. Methodological quality was rated for risk-of-bias, including appropriateness of controls, correction for multiple statistical testing and assessment of heading frequency and head injuries. Results 30 studies with 1691 players were included. Those 57% (8/14) of case–control studies reporting persistent neurocognitive impairment had higher odds for inappropriate control of type 1 errors (OR=17.35 (95% CI (10.61 to 28.36)) and for inappropriate selection of controls (OR=1.72 (1.22 to 2.43)) than studies observing no impairment. Studies reporting a correlation between heading frequency and neurocognitive deficits (6/17) had lower quality of heading assessment (OR=14.20 (9.01 to 22.39)) than studies reporting no such correlation. In 7 of 13 studies (54%), the number of head injuries correlated with the degree of neurocognitive impairment. Abnormalities on neuroimaging (6/8 studies) were associated with subclinical neurocognitive deficits in 3 of 4 studies. Summary/conclusions Various methodological shortcomings limit the evidence for persistent effects of football play on brain structure/function. Sources of bias include low-quality assessment of heading frequency, inappropriate control for type 1 errors and inappropriate selection of controls. Combining neuroimaging techniques with neurocognitive testing in prospective studies seems most promising to further clarify on the impact of football on the brain.
Single Cell Network Profiling (SCNP) to Evaluate the Mechanism of Action of ON 01910.Na, A Novel Clinical Trial Stage Compound.
Authors: David M. Soper, Ying-Wen Huang, Francois Wilhelm, S. C. Cosenza, E. Premkumar Reddy, Alessandra Cesano, Peter L Greenberg, Wendy J. Fantl
Journal: Blood (2009)
Gatekeeping must go beyond the linear referral model
Authors: Jonathan Shapiro
Journal: BMJ (2016)

Greenfield and colleagues’ article on primary care’s gatekeeping role covers only one aspect of primary care;1 excluding other, more important, elements risks these being forgotten entirely.

Their premise is based on a fashionable model of medicine with a simplistic philosophy: “I’m ill. I need treatment. I need to see a specialist as quickly …
구연 : 그랜드볼룸 ; 만성 B형간염, 비호지킨 림프종, 그리고 선제적 항바이러스 치료의 현황 (초)
Authors: 김여명, 송준창, 김종엽, 김진욱, 정숙향
Journal: Clinical and Molecular Hepatology (2010)
Lymphocyte-rich classical Hodgkin's disease (LRCHD): Clinical relevance of a provisional entity
Authors: M Sextro, J Franklin, Ioannis Anagnostopoulos, T Marafioti, H Stein, ML Hansmann, M Harris, NL Harris, ES Jaffe, KO Fransilla, Jhjm VanKrieken, Sibrand Poppema, A Georgii, Carl Diehl
Journal: Blood (1997)
Prognostic relevance of Hormonal Receptor positive Status in HER2-positive Metastatic Breast Cancer Patients: Retrospective Analysis in Real Life
Authors: L. Rinaldi, K. Cannita, V. Cocciolone, P. Lanfiuti Baldi, A. Irelli, S. Paradisi, G. Bruera, A. Cortellini, C. Ficorella, E. Ricevuto
Journal: Annals of Oncology (2015)
Peripheral B Cells from Patients with MGUS and Multiple Myeloma (MM) Can Be Stimulated by Paraprotein-Target Specific T-Helper Cells to Produce Paraprotein-Identical Monoclonal Antibodies: Rationale for PARs, a Novel Therapeutic Approach with Ultimate Specificity in MGUS/MM
Authors: Frank Neumann, Boris Kubuschok, Klaus-Dieter Preuss, Claudia Schormann, Michael Pfreundschuh
Journal: Blood (2015)
Unusual Abdominal and Pelvic Tumors
Authors: P. Morice, A. Thoury, J.C. Sabourin, S. Camatte, D. Atallah, J.P. Armand, P. Madelenat, P. Duvillard, D. Castaigne
Journal: Journal of Clinical Oncology (2003)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2003.12.021 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12972532 Unusual Abdominal and Pelvic Tumors CASE 2. SPONTANEOUS REGRESSION OF PERITONEAL IMPLANTS IN BORDERLINE OVARIAN TUMOR AFTER SALPINGO-OOPHORECTOMY P. MoricexP. MoriceSearch for articles by this author , A. ThouryxA. ThourySearch for articles by this author , J.C. SabourinxJ.C. SabourinSearch for articles by this author , S. CamattexS. CamatteSearch for articles by this author , D. AtallahxD. AtallahSearch for articles by this author , J.P. ArmandxJ.P. ArmandSearch for articles by this author , P. MadelenatxP. MadelenatSearch for articles by this author , P. DuvillardxP. DuvillardSearch for articles by this author , D. CastaignexD. CastaigneSearch for articles by this author Show More Institut Gustave Roussy, Villejuif, France; and Centre Hospitalier Universitaire Bichat, Paris, France https://doi.org/10.1200/JCO.2003.12.021 First Page Full Text PDF Figures and Tables © 2003 by American Society of Clinical Oncology
Same-Day Discharge After Percutaneous Coronary Intervention
Authors: Emily C. Hodkinson, Colm G. Hanratty, Simon J. Walsh
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Metabolic Re-Programming in Notch-Activated T-ALL By mTOR Inhibitor AZD2014 Combined with L-Asparaginase
Authors: Yoko Tabe, Masako Harada, Yuka Miyamae, Tsutomu Fujimura, Saiko Kazuno, Takashi Ueno, Takashi Miida, Michael Andreeff, Marina Konopleva
Journal: Blood (2014)
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)
Authors: M. Martín, A. Chan, L. Dirix, J. O’Shaughnessy, R. Hegg, A. Manikhas, M. Shtivelband, P. Krivorotko, N. Batista López, M. Campone, M. Ruiz Borrego, Q.J. Khan, J.T. Beck, M. Ramos Vázquez, P. Urban, S. Goteti, E. Di Tomaso, C. Massacesi, S. Delaloge
Journal: Annals of Oncology (2016)
Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases
Authors: Hironori Uruga, Emine Bozkurtlar, Tiffany G. Huynh, Alona Muzikansky, Yasushi Goto, Maria Gomez-Caraballo, Aaron N. Hata, Justin F. Gainor, Eugene J. Mark, Jeffrey A. Engelman, Michael D. Lanuti, Mari Mino-Kenudson
Journal: Journal of Thoracic Oncology (2016)
Deletion Of Samsn1 Underlies Genetic Susceptibility To Monoclonal Gammopathy Of Undetermined Significance (MGUS) In Mice
Authors: Sarah Amend, Liang Chu, Daniel Serie, Celine M Vachon, Lan Lu, Ravi Vij, Graham A Colditz, Katherine N Weilbaecher, Michael H. Tomasson
Journal: Blood (2013)
Reduced Intensity BCNU/O6-BG Selection of MGMT-P140K Transduced Hematopoietic Stem Cells Is Efficient at Reduced Toxicity and Leads to an Unrestricted Oligoclonal Differentiation of Modified Murine Repopulating Stem Cells.
Authors: C. Ball, M. Schmidt, I. Pilz, S. Fessler, C. von Kalle, H. Glimm
Journal: Blood (2004)
The Use Of Plerixafor In Hard-To-Mobilize Lymphoma and Multiple Myeloma Patients Not Only Provide Sufficient Numbers Of Pbpcs To Proceed To High Dose Therapy, But Also Have a Positive Impact On Survival
Authors: Dag Josefsen, Geir Hetland, Yngvar Fløisand, Harald Holte, Gunnar Kvalheim
Journal: Blood (2013)
A Phase Ib Study of Obinutuzumab Combined with Lenalidomide for Relapsed/Refractory Follicular B-Cell Lymphoma
Authors: Franck Morschhauser, Gilles Salles, Steven Le Gouill, Herve Tilly, Catherine Thieblemont, Krimo Bouabdallah, Guillaume Cartron, Roch Houot
Journal: Blood (2014)
Hospital-Acquired DVT/PE As “Never Events”: A Misguided Strategy for Performance Improvement in VTE Prevention.
Authors: Brandyn Daniel Lau, Elliott R Haut, Bhunesh Maheshwari, Aileen Almario, Chepkorir Maritim, Deborah Hobson, Peggy S Kraus, Kenneth Shermock, Howard Carolan, Michael B. Streiff
Journal: Blood (2012)